The route by which E2 is administered may be significant in maximizing CVD risk reduction, as transdermal E2 prescribed during perimenopause had no effect on HDL-C but did reduce HDL-CEC compared with placebo ( 8 ).
1
—
—
The route by which E2 is administered may be significant in maximizing CVD risk reduction, as transdermal E2 prescribed during perimenopause had no effect on HDL-C but did reduce HDL-CEC compared with placebo ( 8 ).